They further confirmed that paclitaxel treatment led to the release of CXCL1-enriched EVs from apoptotic TNBC cells (EV-Apo), which were taken up by macrophages, promoting their polarization to the M2 phenotype and enhancing tumor chemoresistance and invasion (72). Here, CXCL1 is linked to neoplasm.